Magnetic Nanoparticles Carry Ampicillin Straight to Resistant Bacteria While Sparing Healthy Cells

Antibiotic resistance has become one of the defining medical challenges of the century, and researchers are increasingly turning to nanotechnology for answers. A new study published in MicrobiologyOpen describes a nanoantibiotic formulation that pairs the familiar beta-lactam drug ampicillin with magnetic iron oxide nanoparticles, using the amino acid L-glutamic acid as a biocompatible bridge between the two. The result is a delivery system that not only kills Gram-positive bacteria but does so while leaving healthy fibroblast cells unharmed, a combination that has proven elusive in many earlier nanoparticle designs.

The research team set out with three goals: to build a novel nanoantibiotic consisting of L-glutamic acid, iron oxide nanoparticles, and ampicillin; to test its antimicrobial effectiveness against representative bacterial strains; and to evaluate its cytotoxicity on mammalian cells. According to the authors, this is the first attempt to use L-glutamic acid as a surface modifier in preparing a conjugate of iron oxide nanoparticles and ampicillin. The choice of coating agent matters enormously, because many commonly used surface modifiers are themselves toxic. The surfactant cetyltrimethylammonium bromide, for example, has repeatedly been shown to damage cells, and one survey of eleven popular coating agents found that six were cytotoxic. L-glutamic acid, a nonessential amino acid naturally tolerated by the body, offers a gentler alternative.

The synthesis itself is elegantly simple. The researchers dissolved L-glutamic acid in methanol, added commercially obtained iron oxide nanoparticles with primary sizes of 18 to 28 nanometers, and stirred the mixture for 24 hours before ultrasonication and filtration. The resulting L-glutamic acid-coated particles were then mixed with ampicillin in water and reacted under magnetic stirring for another day. Unbound antibiotic was washed away, leaving the final formulation, which was stored at 4 degrees Celsius until use. Because the amine groups of glutamic acid can interact with the hydroxide groups on the iron oxide surface, the amino acid acts as a molecular handshake, holding more drug on the particle than an unmodified surface could accommodate.

Characterization confirmed that the assembly worked as intended. Fourier transform infrared spectroscopy revealed the signature amide bands of the amino acid and the characteristic beta-lactam carbonyl peaks of ampicillin within the final formulation, with spectral shifts pointing to hydrogen bonding and electrostatic interactions rather than direct covalent attachment. Energy-dispersive X-ray spectroscopy detected carbon, nitrogen, oxygen, sulfur, and iron, with the sulfur attributable to the antibiotic and the iron to the magnetic core. Dynamic light scattering measured the formulation at roughly 164 nanometers with a negative surface charge of minus 16.6 millivolts, though a polydispersity index of 0.68 indicated a fairly broad size distribution. Notably, in serum-containing media the particles remained close to their original size, suggesting that protein corona formation may actually stabilize the particles in biological environments.

Drug loading proved remarkably efficient. The encapsulation efficiency reached 99.8 percent, with a drug-loading capacity of 18.71 percent by weight. Release experiments in phosphate-buffered saline at physiological pH showed a prolonged profile: cumulative release climbed from about 13 percent at half an hour to 30 percent at two hours, then settled into a slower phase that reached roughly 41 percent by twelve hours. Free ampicillin, by contrast, dumped most of its payload almost immediately and then plateaued. Fitting the release data to kinetic models showed the Korsmeyer-Peppas model gave the best fit, with an exponent value indicating Fickian diffusion as the dominant release mechanism. In practical terms, the formulation can sustain therapeutic concentrations over an extended period, which could reduce dosing frequency in future applications.

Molecular docking provided reassurance that the drug’s pharmacological identity survives conjugation. The team docked the full nanoformulation against penicillin-binding protein 1a, the cell wall enzyme that beta-lactam antibiotics are designed to disable in Gram-positive bacteria. The conjugated formulation showed a binding affinity of minus 9.3 kilocalories per mole, actually slightly better than free ampicillin’s minus 8.8 kilocalories per mole under identical conditions, with largely overlapping contact residues. Polar residues such as serine, threonine, lysine, and arginine contributed hydrogen bonds, while aromatic residues provided hydrophobic stabilization. The binding cavity of 1711 cubic angstroms offered ample room for the bulky conjugate, suggesting the nanoparticle does not obstruct the drug’s ability to recognize its target.

Antimicrobial testing told a nuanced story. In agar well diffusion assays, both free ampicillin and the nanoformulation inhibited Staphylococcus aureus and Bacillus cereus in a concentration-dependent manner, though the nanoparticle version produced somewhat smaller inhibition zones, likely because larger particles diffuse more slowly through agar. The minimum inhibitory concentration results were more revealing: against B. cereus, the nanoformulation actually outperformed free ampicillin, requiring 31.2 micrograms per milliliter versus 62.5 for the free drug. Against S. aureus, free ampicillin retained the edge at 7.8 micrograms per milliliter versus 15.6 for the formulation. Growth kinetic experiments showed that neither bacterium could sustain growth in the presence of either treatment, with S. aureus growth completely arrested for the entire ten-hour observation window.

The mechanism behind the killing appears to involve both classical beta-lactam action and oxidative stress. Reactive oxygen species measurements using the DCFH-DA fluorescent probe showed significantly elevated ROS levels in treated bacteria, with the nanoformulation generating more oxidative stress than free ampicillin in both species. Flow cytometry with the LIVE/DEAD BacLight kit quantified the damage: nonviable cell fractions reached about 52 percent for S. aureus and 18 percent for B. cereus after treatment. Transmission electron microscopy then revealed the physical evidence, showing nanoparticles adhered to bacterial membranes, membrane protrusions indicating disrupted integrity, and electron-dense regions inside the cells. Confocal microscopy of dye-labeled formulation confirmed that the particles are internalized and distributed throughout the cell body, not merely stuck to the surface.

Perhaps the most clinically significant finding came from the cytotoxicity assays. When L929 fibroblast cells were exposed to the nanoformulation at concentrations ranging from 6.25 to 500 micrograms per milliliter, none of the tested doses significantly reduced cell viability. Free ampicillin, in stark contrast, decreased fibroblast viability in a concentration-dependent manner across most of the same range. This reversal of the toxicity profile, in which the nanoparticle version is safer to healthy cells than the free drug, is precisely what nanomedicine theorists have promised for years. The authors attribute this to the biocompatible amino acid coating and the controlled release behavior, which limits the burst exposure of healthy tissue to the antibiotic.

The broader implications extend beyond ampicillin itself. Magnetic nanoparticles can be steered to infection sites using externally applied magnetic fields, potentially delivering antibiotics directly into deep tissue infections while reducing systemic toxicity. Previous work has shown that vancomycin conjugated to magnetic nanoparticles via dopamine can be magnetically directed to targets and remains potent against both Gram-positive and Gram-negative bacteria, and that nanoparticle formulations can restore the effectiveness of glycopeptide antibiotics against resistant strains. The present study adds a crucial piece to this puzzle: a coating strategy that is cheap, biologically benign, and effective at holding beta-lactam drugs in place. While the work remains at the in vitro stage, and the relatively high polydispersity and pH-sensitive aggregation behavior will need attention before clinical translation, the combination of preserved target binding, enhanced activity against B. cereus, amplified oxidative stress in bacteria, and zero detectable toxicity to fibroblasts makes this L-glutamic acid-functionalized magnetic platform a compelling candidate for further in vivo development in the fight against antibiotic-resistant infections.

Subject of Research: A magnetic iron oxide nanoparticle delivery system conjugated with ampicillin via L-glutamic acid for targeted antibacterial therapy

Article Title: A Novel Nanoantibiotic Formulation With Magnetic and Targeting Potential: Ampicillin‐Conjugated L‐glu–Fe3O4 NPs

Article References: Demirel, M., Baris, O., Taskin, M., Albayrak, S., Aysin, F., Aliyeva, A., & Bakan, B. (2026). A Novel Nanoantibiotic Formulation With Magnetic and Targeting Potential: Ampicillin‐Conjugated L ‐glu–Fe 3 O 4 NPs. MicrobiologyOpen, 15(5), Article e70419. https://doi.org/10.1002/mbo3.70419

Image Credits: AI Generated

DOI: 10.1002/mbo3.70419

Keywords: nanoantibiotics, magnetic nanoparticles, ampicillin, L-glutamic acid, iron oxide nanoparticles, antibiotic resistance, drug delivery, Staphylococcus aureus, Bacillus cereus, reactive oxygen species, cytotoxicity, controlled release